Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review

Key Takeaways:

• A Cochrane review of 17 randomized trials (20,342 participants) found that anti-amyloid Alzheimer’s antibodies provide little to no clinically meaningful improvement in memory, cognition or dementia severity over approximately 18 months.
• The analysis also identified an increased risk of treatment-related brain abnormalities on imaging, including swelling and microbleeds, highlighting ongoing safety considerations alongside limited clinical benefit.
• Findings suggest that removing amyloid-beta does not reliably translate into meaningful patient outcomes, reinforcing calls to prioritize alternative disease-modifying targets in Alzheimer’s research.

A new Cochrane review questions how much anti-amyloid Alzheimer’s drugs benefit patients in the early stages of the disease. The review looked at 17 randomized controlled trials involving 20,342 people. The authors found that these drugs had very limited effects on memory, thinking and overall dementia severity after about 18 months of treatment. Any benefit in daily function was “small at best,” according to the paper.

The review analyzed seven amyloid-beta-targeting monoclonal antibodies, including aducanumab, donanemab, gantenerumab, lecanemab and solanezumab, in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Most studies compared the drugs with placebo and followed patients for around 18 months.

These drugs are designed to remove amyloid-beta, a protein that builds up in the brain in Alzheimer’s disease. The hope was that clearing this protein might slow the disease. However, the review found that removing amyloid did not appear to translate into clinically meaningful benefit for patients.

Using moderate-certainty evidence, the review found that the drugs “probably result in little to no difference” in cognitive function compared with placebo. This conclusion was based on pooled results from standard cognitive measures like the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, where the average effect size fell in the trivial range.

A similar pattern appeared for dementia severity. Measured mainly with the Clinical Dementia Rating Sum of Boxes, or CDR-SB, the pooled effect was again judged trivial or near-null. The review stated that the drugs “may result in little to no difference” in dementia severity.

Results on daily functioning varied more. On one commonly used measure of daily activities, the Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale, or ADCS-ADL, the pooled effect was again trivial. However, other scales that focused on complex tasks, such as shopping, handling finances or taking medication, suggested small benefits in some studies. Still, the review authors concluded that any functional effect was “small at best.”

According to the review, a drug can slightly change scores used in clinical trials without making a meaningful difference in patients’ lives. This distinction supports the authors’ conclusion that the measured benefits were limited.

The review found a higher risk of amyloid-related imaging abnormalities, or ARIA, seen on brain scans during treatment. These can include brain swelling, called ARIA-E, and small bleeding spots in the brain, known as ARIA-H.

After 18 months, brain swelling was observed in about 119 per 1,000 people treated with these drugs, compared with 12 per 1,000 people given placebo. For ARIA-H, the review authors did not combine the 18-month results into a single pooled estimate because the three studies reporting that outcome showed high heterogeneity, meaning the direction and size of effect differed too much across trials.

At the same time, the review did not find an increase in serious adverse events or deaths from any cause over the 18-month study period.

The review highlighted important limits in the evidence. Most studies were relatively short for a disease that worsens over years, making it harder to judge longer-term benefits and harms. Reporting of both benefits and harms was often inconsistent across trials. Many studies also did not clearly separate ARIA seen only on scans from ARIA that caused symptoms, leaving less clarity on how clinically important some of these side effects were for patients.

The authors also pointed to a possible source of bias known as functional unblinding. Treated patients were more likely to have noticeable side effects, which might have led participants and investigators to guess who was receiving the active drug instead of placebo. The review viewed this as a concern for several effectiveness outcomes, especially those based on clinical scoring rather than hard endpoints.

All included trials were funded by industry, and the authors said sponsor influence on analysis, interpretation and reporting could not be ruled out. They also identified six ongoing studies, meaning the evidence base could still evolve. 

Even so, the review concluded that successful amyloid removal “does not seem to be associated with clinically meaningful effects” in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, while noting that the “net benefit in clinical practice” of anti-amyloid antibodies remains debated and that regulatory and reimbursement decisions vary across countries.

This review draws attention because Cochrane analyses are widely used to assess the overall evidence on a treatment issue, not just the results of a single trial. Such reviews can influence how clinicians, guideline groups and health systems view a drug class. 

The paper has already received outside reaction. BBC News reported feedback from some Alzheimer’s researchers who argued that combining older failed antibodies with newer ones may blur important differences between drugs. BBC News also reported support for the review’s cautious interpretation from longtime critics of the anti-amyloid approach.

Work around anti-amyloid treatment is continuing in monitoring and drug development. In March 2026, Cortechs.ai and Siemens Healthineers announced plans to expand access to imaging tools that can help monitor ARIA in treated patients. Earlier, in January 2026, SciNeuro announced a deal with Novartis tied to a next-generation amyloid-beta antibody program aimed at improving brain delivery.